Next-generation CAR-T therapy for glioblastoma

GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.

Our Technology

• Dual-mechanism CAR-T cells targeting tumor antigens and the myeloid compartment  
• Local secretion of a CD47-blocking molecule to reprogram tumor-associated macrophages  
• Designed to overcome immune suppression and tumor heterogeneity in solid tumors